{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:36:07Z","timestamp":1788568567051,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Noscendo"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While intensive protocols in onco-haematology have improved survival rates for patients with haematological malignancies, they have also resulted in an increased incidence of infection associated with therapy-induced immunosuppression (including chemotherapy-induced febrile neutropenia; FN). The occurrence of FN, associated with high morbidity and mortality, necessitates broad-spectrum antibiotic therapy, occasioning delayed chemotherapy and resulting in a loss of opportunity for the patient. Considering that without an identified pathogen, a 10% mortality rate can ensue, documentation is essential to the optimisation of antibiotic therapy. However, blood culture (the reference test) is limited for several reasons: such as fastidious culture, antibiotic treatment prior to sampling or insufficient sample volume. Sequencing technologies have led to the development of diagnostic approaches based on the detection of circulating DNA in blood. This study will aim to assess the clinical utility of metagenomic next-generation sequencing (mNGS)-DISQVER technology in detecting pathogenic microorganisms from blood samples of patients undergoing high-risk FN treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This nationwide, prospective, multicentre, interventional, proof-of-concept clinical trial will enrol 200 patients. Will include patients\u226518 years old, treated for malignancy, at high risk of FN (Multinational Association for Supportive Care in Cancer score\u226421) with an expected duration of neutropenia\u22657\u2009days. Patients who received antibiotic treatment within 24 hours prior to enrolment, have previously participated and\/or have enhanced protection will be excluded. The primary outcome will be determined by considering the microorganisms responsible for this FN, weighted by the assessment of an adjudication committee. Secondary outcomes will evaluate patient management depending on the arm. The second secondary outcome will be determined by the duration of conventional assessment, frequency of microorganisms detected during routine care and percentage distribution of theoretical adjustments made to anti-infective treatment based on microorganisms diagnosed using the mNGS-DISQVER tool as compared with conventional practices. Identifying the pathogens responsible for high-risk FN from a blood sample, using an unbiased technique, can provide microbiological documentation and may even reveal unexpected microorganisms in these profoundly immunocompromised patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The protocol received approval from the Comit\u00e9 de Protection des Personnes Sud-M\u00e9diterran\u00e9e II. All participants will provide informed consent before participation. The trial has been registered on ClinicalTrials.gov (identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06075888\">NCT06075888<\/jats:ext-link>\n                      ). The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06075888\">NCT06075888<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087773","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:42:08Z","timestamp":1737585728000},"page":"e087773","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic performance of the DISQVER metagenomic sequencing tool for the identification of pathogens in febrile neutropenic patients: the ADNEMIA trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06075888","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06075888","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06075888","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3732-6894","authenticated-orcid":false,"given":"Maxime","family":"Pichon","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire de Poitiers, Infectious Agents Department, Bacteriology Laboratory, Poitiers, France"},{"name":"University of Poitiers, INSERM U1070 PHAR2 Pharmacology of Antimicrobial Agents and Resistance, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Burucoa","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Poitiers, Infectious Agents Department, Bacteriology Laboratory, Poitiers, France"},{"name":"University of Poitiers, INSERM U1070 PHAR2 Pharmacology of Antimicrobial Agents and Resistance, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2025121605201756000_15.1.e087773.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70282-7"},{"key":"2025121605201756000_15.1.e087773.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.06.025"},{"key":"2025121605201756000_15.1.e087773.3","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1007\/s00277-003-0766-2","article-title":"Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"82 Suppl 2","author":"Buchheidt","year":"2003","journal-title":"Ann Hematol"},{"key":"2025121605201756000_15.1.e087773.4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"2025121605201756000_15.1.e087773.5","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.respe.2021.05.013","article-title":"Hospitalisations pour neutrop\u00e9nie f\u00e9brile chimio-induite en France en 2018: impact clinique et caract\u00e9ristiques des patients \u00e0 partir des donn\u00e9es de la base PMSI","volume":"69","author":"Freyer","year":"2021","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"key":"2025121605201756000_15.1.e087773.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090020019005"},{"key":"2025121605201756000_15.1.e087773.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560847"},{"key":"2025121605201756000_15.1.e087773.8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jped.2015.08.008","article-title":"Acute Myeloid Leukemia: analysis of epidemiological profile and survival rate","volume":"92","author":"de Lima","year":"2016","journal-title":"J Pediatr (Rio J)"},{"key":"2025121605201756000_15.1.e087773.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"2025121605201756000_15.1.e087773.10","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00134-017-4947-1","article-title":"Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Med"},{"key":"2025121605201756000_15.1.e087773.11","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45554"},{"key":"2025121605201756000_15.1.e087773.12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/cid\/ciab742","article-title":"Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia","volume":"74","author":"Eichenberger","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025121605201756000_15.1.e087773.13","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1097\/CCM.0000000000003658","article-title":"Enhanced Performance of Next-Generation Sequencing Diagnostics Compared With Standard of Care Microbiological Diagnostics in Patients Suffering From Septic Shock","volume":"47","author":"Grumaz","year":"2019","journal-title":"Crit Care Med"},{"key":"2025121605201756000_15.1.e087773.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.12.006"},{"key":"2025121605201756000_15.1.e087773.15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac393","article-title":"Pathogen Detection by Metagenomic Next-Generation Sequencing During Neutropenic Fever in Patients With Hematological Malignancies","volume":"9","author":"Schulz","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025121605201756000_15.1.e087773.16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12879-022-07662-2","article-title":"Plasma metagenomic next-generation sequencing of microbial cell-free DNA detects pathogens in patients with suspected infected pancreatic necrosis","volume":"22","author":"Hong","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025121605201756000_15.1.e087773.17","doi-asserted-by":"crossref","first-page":"688272","DOI":"10.3389\/fped.2021.688272","article-title":"A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies","volume":"9","author":"Nijman","year":"2021","journal-title":"Front Pediatr"},{"key":"2025121605201756000_15.1.e087773.18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"2025121605201756000_15.1.e087773.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70017-8"},{"key":"2025121605201756000_15.1.e087773.20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/23744235.2018.1438649","article-title":"Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study","volume":"50","author":"Le Clech","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"2025121605201756000_15.1.e087773.21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx226","article-title":"Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review","volume":"4","author":"Snyder","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2025121605201756000_15.1.e087773.22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1078155219865303","article-title":"Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin","volume":"26","author":"Petteys","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2025121605201756000_15.1.e087773.23","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/jac\/dkac190","article-title":"Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study","volume":"77","author":"Paret","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025121605201756000_15.1.e087773.24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s15010-024-02300-2","article-title":"Metagenomic next-generation sequencing as a diagnostic tool in the clinical routine of an infectious diseases department: a retrospective cohort study","volume":"52","author":"Kalbitz","year":"2024","journal-title":"Infection"},{"key":"2025121605201756000_15.1.e087773.25","doi-asserted-by":"crossref","unstructured":"Balks J , Grumaz S , Mazzitelli S , et al . Microbial cell-free DNA-sequencing as an addition to conventional diagnostics in neonatal sepsis. Pediatr Res 2024. doi:10.1038\/s41390-024-03448-1","DOI":"10.1038\/s41390-024-03448-1"},{"key":"2025121605201756000_15.1.e087773.26","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/jcm12041466","article-title":"Next-Generation Sequencing in Critically Ill COVID-19 Patients with Suspected Bloodstream Infections: A Retrospective Cohort Study","volume":"12","author":"Leitl","year":"2023","journal-title":"J Clin Med"},{"key":"2025121605201756000_15.1.e087773.27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/jcm13020306","article-title":"The Value of Next-Generation Sequencing in Diagnosis and Therapy of Critically Ill Patients with Suspected Bloodstream Infections: A Retrospective Cohort Study","volume":"13","author":"Overbeek","year":"2024","journal-title":"J Clin Med"},{"key":"2025121605201756000_15.1.e087773.28","doi-asserted-by":"crossref","unstructured":"Yang M , Tao C . Diagnostic efficiency of the FilmArray blood culture identification (BCID) panel: a systematic review and meta-analysis. J Med Microbiol 2023;72. doi:10.1099\/jmm.0.001608","DOI":"10.1099\/jmm.0.001608"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:20:25Z","timestamp":1765891225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-087773"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087773","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}